Biotech & AI drug discoveryNature Medicine

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

The International Neoadjuvant Melanoma Consortium (INMC) released an updated pooled analysis on five-year survival with neoadjuvant therapy in melanoma. The available context provides no further details.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-01T00:00:00+00:00

Published here2026-10-02T17:49:11+00:00

Original source

Nature Medicine

Media report · consult original reporting

Read the original ↗https://www.nature.com/articles/s41591-026-04677-z

Original headline

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.